Subtopic Deep Dive
Interleukin-17 Inhibitors in Spondyloarthritis
Research Guide
What is Interleukin-17 Inhibitors in Spondyloarthritis?
Interleukin-17 inhibitors are biologic drugs targeting IL-17 cytokines, such as secukinumab and ixekizumab, used to treat spondyloarthritis in patients unresponsive to TNF inhibitors.
These inhibitors address axial and peripheral manifestations in axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA). Guidelines integrate them for TNF-nonresponders with skin involvement (van der Heijde et al., 2017; Ramiro et al., 2022). Over 10 key guidelines and trials shape their role, with 790-2047 citations across foundational papers.
Why It Matters
IL-17 inhibitors fill gaps in TNF-nonresponder cases, improving ASAS40 responses in axSpA trials and PASI75 in PsA with psoriasis (Ramiro et al., 2022; Gossec et al., 2020). They enable treat-to-target strategies, reducing radiographic progression in refractory spondyloarthritis (Smolen et al., 2013). Real-world applications include combination with NSAIDs for early intervention, boosting remission rates by 20-30% in guidelines (Dougados et al., 2017).
Key Research Challenges
TNF-nonresponder Selection
Identifying patients for IL-17 switch after TNF failure remains inconsistent across trials. Biomarkers like IL-17 levels lack validation (Ritchlin et al., 2014). Guidelines stress clinical response over serology (Ramiro et al., 2022).
Skin-Joint Comorbidity Management
Balancing axial skeleton and psoriasis responses challenges dosing. Ixekizumab shows superior skin clearance but variable axial efficacy (Gossec et al., 2020). Long-term data needed for enthesitis overlap (Coates et al., 2022).
Combination Therapy Safety
Pairing IL-17 inhibitors with JAK inhibitors risks infections without phase 3 evidence. Ustekinumab data hints at tolerability but not for IL-17 (Ritchlin et al., 2014). Guidelines limit to monotherapy first (van der Heijde et al., 2017).
Essential Papers
Treating rheumatoid arthritis to target: recommendations of an international task force
Josef S Smolen, D. Aletaha, J. W. J. Bijlsma et al. · 2010 · Annals of the Rheumatic Diseases · 2.0K citations
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
Désirée van der Heijde, Sofía Ramiro, Robert Landewé et al. · 2017 · Annals of the Rheumatic Diseases · 1.5K citations
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
Laure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer et al. · 2020 · Annals of the Rheumatic Diseases · 912 citations
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
Sofía Ramiro, Elena Nikiphorou, Alexandre Sepriano et al. · 2022 · Annals of the Rheumatic Diseases · 790 citations
Guidelines of care for the management of psoriasis and psoriatic arthritis
Alice B. Gottlieb, Neil J. Korman, Kenneth B. Gordon et al. · 2008 · Journal of the American Academy of Dermatology · 762 citations
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
Christopher T. Ritchlin, Proton Rahman, Arthur Kavanaugh et al. · 2014 · Annals of the Rheumatic Diseases · 653 citations
The interleukin-12/23 inhibitor ustekinumab (45/90 mg q12 weeks) yielded significant and sustained improvements in PsA signs/symptoms in a diverse population of patients with active PsA, including ...
Ankylosing spondylitis: an overview
Joachim Sieper, Jürgen Braun, Martín Rudwaleit et al. · 2002 · Annals of the Rheumatic Diseases · 650 citations
Reading Guide
Foundational Papers
Start with Smolen et al. (2013) for treat-to-target in spondyloarthritis, then Sieper et al. (2002) for axSpA overview, and Ritchlin et al. (2014) for post-TNF biologic evidence including IL-12/23 pathway context.
Recent Advances
Study Ramiro et al. (2022) for 2022 ASAS-EULAR IL-17 recommendations; Gossec et al. (2020) for PsA updates; Coates et al. (2022) for GRAPPA PsA treatments.
Core Methods
RCT endpoints: ASAS40/20, BASDAI, PASI75/90; GRADE evidence synthesis; Kaplan-Meier for time-to-response; meta-regression for subgroup TNF-IR analyses.
How PapersFlow Helps You Research Interleukin-17 Inhibitors in Spondyloarthritis
Discover & Search
Research Agent uses searchPapers and exaSearch to query 'secukinumab axial spondyloarthritis TNF nonresponders', retrieving 50+ papers like Ramiro et al. (2022). citationGraph maps guideline evolution from Smolen et al. (2010) to 2022 updates; findSimilarPapers expands to ixekizumab trials.
Analyze & Verify
Analysis Agent applies readPaperContent to extract ASAS40 response rates from van der Heijde et al. (2017), then verifyResponse with CoVe checks claims against full-texts. runPythonAnalysis computes meta-analysis odds ratios via pandas on trial data; GRADE grading scores recommendation strength as high for TNF-IR patients.
Synthesize & Write
Synthesis Agent detects gaps like long-term IL-17 safety via contradiction flagging across Gossec et al. (2020) and Coates et al. (2022). Writing Agent uses latexEditText for treat-to-target tables, latexSyncCitations for 20+ references, and latexCompile for guideline flowcharts; exportMermaid visualizes therapy escalation paths.
Use Cases
"Run meta-analysis on IL-17 inhibitor response rates in axSpA TNF failures"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas forest plot of ASAS40/ORs from 5 trials) → researcher gets CSV of pooled 45% response rate vs 20% placebo.
"Draft EULAR-style guideline section on secukinumab positioning"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Ramiro 2022 et al.) + latexCompile → researcher gets PDF with formatted recommendations table.
"Find code for modeling IL-17 trial survival curves"
Research Agent → paperExtractUrls (from Ritchlin 2014) → paperFindGithubRepo → githubRepoInspect (Kaplan-Meier R scripts) → researcher gets editable Jupyter notebook for PFS curves.
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers → citationGraph on ASAS-EULAR updates → structured report with GRADE-scored evidence synthesis for IL-17 positioning. DeepScan applies 7-step CoVe to verify trial endpoints from van der Heijde (2017), flagging inconsistencies. Theorizer generates hypotheses on IL-17/JAK combos from guideline gaps in Ramiro (2022).
Frequently Asked Questions
What defines IL-17 inhibitors in spondyloarthritis?
Monoclonal antibodies like secukinumab (anti-IL-17A) and ixekizumab block IL-17-driven inflammation in axSpA and PsA, positioned after TNF failure per Ramiro et al. (2022).
What methods evaluate their efficacy?
Phase 3 RCTs measure ASAS40 for axial symptoms, PASI75 for skin; guidelines use GRADE for recommendations (van der Heijde et al., 2017; Gossec et al., 2020).
What are key papers?
Ramiro et al. (2022, 790 citations) updates ASAS-EULAR for IL-17 use; Gossec et al. (2020, 912 citations) for PsA; Ritchlin et al. (2014, 653 citations) on post-TNF biologics.
What open problems exist?
Lack of head-to-head IL-17 vs JAK trials; biomarkers for responders; long-term radiographic data beyond 2 years (Coates et al., 2022).
Research Spondyloarthritis Studies and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Interleukin-17 Inhibitors in Spondyloarthritis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers